New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets

Project Information

PROTOCOL

Grant agreement ID: 673280

DOI

10.3030/673280

Project closed

EC signature date 23 April 2015

Start date 1 May 2015

End date 31 October 2015

Funded under

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

CIDQO 2012 SL
Spain

Periodic Reporting for period 1 - PROTOCOL (New processing technology for colistmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets)

Reporting period: 2015-05-01 to 2015-10-31

Summary of the context and overall objectives of the project

The PROTOCOL project (new PROcessing Technology fOr COListmethate sodium, leading to improved and cost-effective formulations for pharmaceutical and veterinary markets) aimed through SME Instrument Phase 1 to perform a thorough feasibility study to verify the practical and economic viability in Pharmaceutical and Veterinary markets of the CMS form. The specific objectives that were defined, and have been covered in the frame of the 1st Stage of SME Instrument are:
- To develop a business and exploitation plan.
- To undertake a commercial feasibility assessment.
- To widely disseminate project outcomes.
- To define the best practices for IPR management.
- To analyze in detail the regulatory standards to be met.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The general goal of the current project is to fulfill the need of decreasing the current CMS market price and to undertake an innovation project to solve this limitation, through a new process to obtain CMS. In this sense, CIDQO has concluded that carrying the innovation project and launching CMS on the company’s specifications can be a successful business.

This period of time has been useful for specifying relevant elements of the business model and the tasks regarding to develop the exploitation model, undertaking the commercial feasibility assessment comprising logistics and marketing plan, disseminating the project outcomes, define the best practices for IPR management and analysing in detail the regulatory standards in order to ensure the success for commercial exploitation of the PROTOCOL’s results.

Summarizing:
• Launching CIDOQ’s cost-effective CMS through the new processing technology is a project with high margin
• A full market study has been undertaken.
• An IP study has been carried out.
• The project outcomes have been widely disseminated.
• SME Instrument Phases II and III will further develop the innovation.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The expected growth of the company after the current SME Instrument Phase 1 and the subsequent Phase 2 will be very important. CIDQO should increase its net incomes and hence it foresees the creation of several new employments.

COListmethate sodium